stockrow
Wednesday 11 November 2026
Export REPL’s income statement to Excel — free account
Replimune Group, Inc.
REPL- EPS
- +39.7%
- Free cash flow
- +42.2%
- Total debt
- +74.3%
Quarter to September 2026, against a year earlier
21.88
1.40
−6.01%
Follow REPL
Alert me
Replimune Group, Inc. (REPL) Net income
Replimune Group, Inc.'s net income for fiscal 2026 was −$313.9M, compared with −$247.3M in fiscal 2025. Over the twelve months to 30 September 2026 it was −$271.0M. Over the past ten years it has ranged from −$313.9M (fiscal 2026) to −$7.7M (fiscal 2017) — the current reading is the lowest in ten years. Net income has fallen for 9 consecutive fiscal years. Replimune Group, Inc. ranks 549th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2026 | −$313.9M | — |
| FY2025 | −$247.3M | — |
| FY2024 | −$215.8M | — |
| FY2023 | −$174.3M | — |
| FY2022 | −$118.0M | — |
| FY2021 | −$80.9M | — |
| FY2020 | −$52.6M | — |
| FY2019 | −$30.8M | — |
| FY2018 | −$19.7M | — |
| FY2017 | −$7.7M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | −$57.1M | — |
| Jun 2026 | −$69.8M | — |
| Mar 2026 | −$73.2M | — |
| Dec 2025 | −$70.9M | — |
| 35 more quarters | Free account |
Against its own ten years
Low −$313.9M
High −$7.7M
Ten-year median
−$99.5M
Current reading's percentile
10
Net income against peers
| Company | Net income |
|---|---|
| AUPH Aurinia Pharmaceuticals Inc compare | $314.3M |
| ZYME Zymeworks Inc. compare | $43.3M |
| TRAX First Tracks Biotherapeutics, Inc. compare | $16.3M |
| VIR Vir Biotechnology, Inc. compare | −$184.8M |
| REPL Replimune Group, Inc. | −$271.0M |
| IMNM Immunome, Inc. compare | −$282.6M |
| VERA Vera Therapeutics, Inc. compare | −$401.9M |
| RXRX Recursion Pharmaceuticals, Inc. compare | −$475.7M |
| LKFT Lakefront Biotherapeutics - Sponsored ADR compare | −$652.4M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item